[Skip to Navigation]
Sign In
Views 577
Citations 0
Editorial
August 4, 2022

Reforming Patient Cost Sharing for Cancer Medications in Medicare Part D

Author Affiliations
  • 1Cancer Innovation and Regulation Initiative, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 2Division of Urological Surgery, Brigham and Women’s Hospital, Boston, Massachusetts
  • 3Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
  • 4Department of Health Policy andVanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee
JAMA Oncol. Published online August 4, 2022. doi:10.1001/jamaoncol.2022.2828

Medicare has one of the most burdensome patient cost-sharing structures for prescription medications in the US. Under Medicare Part D, which covers outpatient prescription drugs, there is no limit to out-of-pocket costs for most beneficiaries, and a substantial portion of out-of-pocket costs is calculated as a percentage of list prices (coinsurance) rather than fixed co-payments. This cost-sharing system places the burden of escalating list prices of cancer medicines on patients, which is associated with reduced medication adherence and negative health outcomes.1

Add or change institution
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×